Physician profile
Charles D Daniel
NPI 1134124035
$94,135.49
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $25K · 2021: $25K · 2022: $6,905 · 2023: $4,529 · 2024: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,585 · Travel and Lodging: $1,492 · Food and Beverage: $324 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,585.00 |
| Travel and Lodging | $1,491.51 |
| Food and Beverage | $323.77 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roanoke Area Surgical Lasers, LLC | $86,350.00 | 2019-2023 | |
| Intuitive Surgical, INC. | $6,165.49 | 2019-2023 | Da Vinci Sp, Da Vinci Surgical System |
| Astellas Pharma US INC | $399.26 | 2019-2023 | Xtandi |
| Teleflex LLC | $206.63 | 2021-2022 | |
| Coloplast Corp | $190.20 | 2019-2021 | |
| Myovant Sciences INC. | $171.16 | 2021-2022 | |
| Urovant Sciences INC | $152.22 | 2021-2022 | |
| Procept Biorobotics Corporation | $150.88 | 2024 | Aquabeam System |
| Bayer Healthcare Pharmaceuticals INC. | $55.47 | 2019-2020 | |
| Urogen Pharma, INC. | $48.47 | 2022 | |
| Blue Earth Diagnostics | $46.41 | 2019-2021 | |
| Pfizer INC. | $43.30 | 2021-2022 | |
| Boston Scientific Corporation | $32.09 | 2019-2020 | |
| Abbvie INC. | $30.56 | 2019-2022 | |
| Accord Healthcare, INC. | $20.79 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $20.66 | 2022 | |
| Myriad Genetic Laboratories, INC. | $18.11 | 2022 | |
| Allergan, INC. | $17.78 | 2019 | |
| Dendreon Pharmaceuticals LLC | $16.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$188,710.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.